Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,063.56 -21.63 (-1.99%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Stocks to Love in 2026 ↗
Are you looking for investment opportunities in 2026? 
Via The Motley Fool
Topics ETFs Initial Public Offering
News headline image
Can This Stock Double Again in 2026? ↗
It's a tough act to follow. 
Via The Motley Fool
News headline image
Is the Schwab U.S. Dividend Equity ETF a Buy Now? ↗
It's time to start thinking strategically -- and even philosophically -- about how seemingly similar funds are actually quite different. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗
It has strong momentum thanks to its current portfolio and several catalysts on the horizon. 
Via The Motley Fool
News headline image
Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?
Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels. 
Via Barchart.com
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive... 
Via MarketMinute
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
News headline image
The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance
As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company... 
Via MarketMinute
Topics Economy
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
News headline image
The WeightWatchers Rebirth: A Clinical Transformation and the GLP-1 Era
As of January 9, 2026, WW International, Inc. (NASDAQ: WW), better known as WeightWatchers, stands at the most pivotal juncture in its 63-year history. After a tumultuous 2024 and 2025 that saw the... 
Via PredictStreet
Topics Artificial Intelligence Bankruptcy
News headline image
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight ↗
Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz alone in a late-stage trial. 
Via Benzinga
News headline image
The Great Rotation: Investors Pivot to Defensive Moats as Tech Giants Face 'AI ROI' Audit
As the first full trading week of 2026 comes to a close, a seismic shift is rattling Wall Street. The high-flying technology sector, which dominated the market narrative throughout 2024 and 2025, is... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
U.S. Trade Deficit Plummets to 2009 Levels as 'Liberation Day' Tariffs and Gold Surge Reshape Global Trade
On January 8, 2026, the U.S. Bureau of Economic Analysis and the Census Bureau released a landmark report revealing that the nation’s trade deficit has narrowed to its lowest level since the height of... 
Via MarketMinute
Topics Economy Supply Chain World Trade
News headline image
Apple Shares Retreat 7% as Memory Cost Surge and 'Great Rotation' Reset Tech Valuations
The start of 2026 has brought a cold front to Silicon Valley as Apple Inc. (NASDAQ:AAPL) shares retreated 7% from their December all-time highs. This downturn, which has wiped out over $200 billion in... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains ↗
Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth. 
Via Stocktwits
Topics Initial Public Offering
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal ↗
Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40%. 
Via Investor's Business Daily
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands... 
Via MarketMinute
Topics Economy
News headline image
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal ↗
Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction. 
Via Stocktwits
News headline image
3 Drug Stocks to Buy at a Discount ↗
The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider. 
Via The Motley Fool
News headline image
The Valuation Wall: Nasdaq Momentum Stalls as the 'Great Rotation' of 2026 Takes Hold
The relentless surge that propelled the technology sector to historic heights throughout 2024 and 2025 has hit a significant roadblock in the opening week of 2026. As of January 7, 2026, the tech-heavy... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Great Rotation: How the 2026 Market Rally Outgrew the 'Magnificent Seven'
As the first week of trading in 2026 comes to a close, the S&P 500 has once again shattered records, crossing the 7,500 threshold with a momentum that feels fundamentally different from the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
This Could Be Key to Pfizer's Turnaround in 2026 ↗
Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition ↗
Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.